Dr. Rahul Bhargava is a senior Haematologist and Bone Marrow Transplant specialist serving as Principal Director and Chief – Haematology, Haemato-Oncology and Bone Marrow Transplant at Fortis Memorial Research Institute, Gurugram. With more than 23 years of experience, he specialises in the management of complex blood disorders and advanced stem cell transplantation.
He completed his MBBS and MD in General Medicine, followed by a DM in Clinical Haematology from the All India Institute of Medical Sciences (AIIMS), New Delhi, in 2009. His specialist training has provided a strong foundation for his work in benign and malignant blood disorders and advanced transplant medicine.
His clinical expertise includes bone marrow transplantation, autologous and allogeneic stem cell transplantation, haploidentical transplantation, CAR-T cell therapy and the management of leukaemia, lymphoma, multiple myeloma, aplastic anaemia and thalassaemia.
Before joining Fortis, Dr. Bhargava worked at Medanta – The Medicity and Artemis Hospital, Gurugram, and Christian Medical College, Vellore. He has also contributed to developing stem cell transplant programmes in India and has received recognition for his academic performance during his MD and DM training.
Decades of expertise, pioneering breakthroughs, and a proven record — here is why patients from 120+ countries trust Dr. Bhargava for blood disorder care.
Over 1,500 bone marrow and stem cell transplants — one of the highest volumes in Asia — with a >95% engraftment success rate.
First Indian doctor to popularize haematopoietic stem cell transplants for aggressive MS in 2016, changing lives globally.
Dr. Bhargava's team has successfully guided patients from Nigeria, Iraq, Bangladesh, the UK, Ukraine, and 115+ more nations.
Set up low-cost transplant centres at Batra, Sarvodaya, Action Balaji and more — making curative BMT accessible to all.
DM in Clinical Hematology from AIIMS New Delhi — India's top medical institute. Recipient of the MedAchievers Healthcare Icon Award and Best Doctor Award.
Every case is personally reviewed by Dr. Bhargava. Treatment plans are tailored, transparent, and discussed in detail before travel.
Leukemia (AML, CML, CLL, ALL), Lymphoma (Hodgkin & Non-Hodgkin), Multiple Myeloma — treated with advanced chemotherapy, targeted therapy & stem cell transplant.
Autologous, allogeneic, and haplo-identical BMT for leukemia, lymphoma, aplastic anemia, and inherited blood disorders. 1,500+ transplants performed.
Cutting-edge immunotherapy using genetically modified T-cells to target blood cancers that have relapsed after standard treatments.
Curative BMT for major thalassemia and sickle cell anemia in children and adults. Low-cost BMT programs available across India.
Comprehensive management of hemophilia A & B, Von Willebrand disease, platelet disorders, and other complex coagulopathies.
Both immunosuppressive therapy and stem cell transplantation for severe and very severe aplastic anemia, including pediatric cases.
Pioneer of HSCT (Hematopoietic Stem Cell Transplant) for Multiple Sclerosis in India — a disease-modifying treatment for aggressive MS.
Expert care for blood disorders in children including childhood leukemia, thalassemia, immune thrombocytopenia (ITP), and inherited bone marrow failure syndromes.
Diagnosis and treatment of bone marrow failure and pre-leukemia syndromes with hypomethylating agents and allogeneic stem cell transplantation.
The most complex and potentially curative form of BMT where stem cells come from a matched donor (sibling or unrelated). Used for leukemia, aplastic anemia, and inherited blood disorders.
Patient's own stem cells are harvested, stored, and reinfused after high-dose chemotherapy. Primarily used in multiple myeloma and relapsed lymphomas.
Chimeric Antigen Receptor T-cell therapy — a revolutionary immunotherapy where the patient's own T-cells are genetically reprogrammed to attack cancer cells.
Hematopoietic Stem Cell Transplantation (HSCT) for aggressive relapsing-remitting multiple sclerosis — resets the immune system to halt disease progression.
The only curative treatment for beta-thalassemia major and sickle cell disease through allogeneic stem cell transplantation from an HLA-matched sibling.
Send your medical reports and get a personalised treatment plan from one of India's top hematologists — at no charge. Dr. Bhargava's team reviews cases from 120+ countries and responds within 24 hours.
Share your reports and receive a personalised treatment recommendation within 48 hours — at no cost.